ACC.26 advanced registration ends Feb. 12 – register now!

David Joel Maron, MD, FACC

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Abiomed(SIGNIFICANT), Regeneron(MODEST) EQUITY INTERESTS/STOCK OPTIONS: Ablative Solutions(NONE)

View Full Disclosure